Skin cancer risk from the use of immunosuppressive medications used to treat inflammatory conditions is not well understood, though studies clearly establish an exaggerated risk of skin cancer in solid organ transplant recipients (SOTRs) receiving these medications. The authors report a patient with Behcet's disease treated with combination immunosuppressive therapy and common variable immunodeficiency developing multiple squamous cell carcinomas (SCCs) of the skin, necessitating adjustment of her immunosuppressive regimen. As more patients are treated with immunosuppressive medications for chronic inflammatory diseases, clinicians must be aware of the possible increased risk of skin cancers associated with these medications. Skin cancer risk assessment, screening for sub-clinical malignancies and frequent skin exams of high risk patients may represent strategies to improve the safety of these medications.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study.
Cancer Med
February 2025
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Introduction: Immune checkpoint inhibitors (ICI) have improved the therapeutic arsenal in outpatient oncology care; however, data on necessity of hospitalizations associated with immune-related adverse events (irAEs) are scarce. Here, we characterized hospitalizations of patients undergoing ICI, from the prospective cohort study of the immune cooperative oncology group (ICOG) Hannover.
Methods: Between 12/2019 and 06/2022, 237 patients were included.
A rare intersection: squamous cell carcinoma of the tonsil and the anti-TIF1 syndrome masquerade.
BMC Rheumatol
January 2025
Department of Rheumatology, Overton Brooks VA Medical Center, Shreveport, LA, USA.
Background: Dermatomyositis is a chronic inflammatory condition affecting muscles and skin, often associated with an increased risk of cancer. Specific autoantibodies, including anti-TIF1 (Transcription Intermediary Factor 1), have been linked to this risk. We present a case of dermatomyositis in a male patient positive for anti-TIF1 antibodies, subsequently diagnosed with squamous cell carcinoma of the tonsil, a novel association not previously documented.
View Article and Find Full Text PDFPhase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancer.
NPJ Breast Cancer
January 2025
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Endocrine therapy with CDK4/6 inhibitors is standard for estrogen receptor-positive, HER2-negative metastatic breast cancer (ER+/HER2- MBC), yet clinical resistance develops. Previously, we demonstrated that low doses of palbociclib activate autophagy, reversing initial G1 cell cycle arrest, while high concentrations induce off-target senescence. The autophagy inhibitor hydroxychloroquine (HCQ) induced on-target senescence at lower palbociclib doses.
View Article and Find Full Text PDFFluorescence molecular imaging-guided photodynamic therapy for early breast cancer in the prone position: feasibility evaluation with Monte Carlo simulations.
Photodiagnosis Photodyn Ther
January 2025
Maebashi-Institute of Technology, Systems Life Engineering, Gunma, 371-0816 Japan. Electronic address:
Introduction: The successful diagnosis and treatment of early-stage breast cancer enhances the quality of life of patients. As a promising alternative to recently developed magnetic resonance imaging-guided radiotherapy, we proposed fluorescence molecular imaging-guided photodynamic therapy (FMI-guided PDT), which requires no expensive equipment. In the FMI simulations, ICG-C11 which has emission peaks at near-infrared wavelengths was used as the FMI agent.
View Article and Find Full Text PDFInternal cancers in solid organ transplant recipients with a post-transplant skin cancer: a cohort study.
J Invest Dermatol
January 2025
Department of Health Services Research University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!